Peramivir Anhydrous: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Peramivir Anhydrous. Educational only — not medical advice.
Labeled uses
RAPIVAB is indicated for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than 2 days.
Source: FDA labeling via NIH DailyMed (set fe04f6cd…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.